< Terug naar vorige pagina


Mucin isoforms in diseases characterized by barrier dysfunction

The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections,... In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.
Octrooi-publicatienummer: WO2021013479
Bron: WIPO
Jaar aanvraag: 2020
Jaar van publicatie: 2021
Status: Aangevraagd
Technologiedomeinen: Analysis of biological materials, Pharmaceuticals
Gevalideerd voor IOF-sleutel: Ja